Table 1:

Cases with EGFR L861Q mutation

Patient	Concurrent EGFR alteration	Sex	Age at metastasis	stage	Ethnicity	Smoking	TKI#1	TTD (months)	TKI#2	TTD (months)	TKI#3	TTD (months)
1	S720F	F	61	IV	White	Former	Erlotinib	7.8
2	L747F	M	77	IV	White	Never	Erlotinib	4
3		F	63	IV	White	Never	Erlotinib	1
4		M	59	IV	Asian	Never	Erlotinib	2
5		M	83	IIIA	White	Former	Erlotinib	6
6		F	68	IIIB	Asian	Never	Erlotinib	4.5
7		F	60	IIIA	White	Former	Erlotinib	0.3
8		F	65	IV	White	Former	Erlotinib	4
9		F	66	IV	White	Former	Erlotinib	1.4	Afatinib	22.4	Osimertinib	12.3
10		F	72	IV	White	Former	Erlotinib	11.1	Osimertinib	14.7
11		F	55	IIIA	Asian	Never	Erlotinib	3.7	Osimertinib	3
12		F	54	IV	White	Never	Erlotinib	4.2	Osimertinib	26.2
13		F	86	IV	White	Never	Erlotinib	18.1	Osimertinib	20.5
14	G719S	F	69	IV	White	Former	Erlotinib	12.8
15	G719A	M	68	IV	White	Former	Afatinib	9.3
16	G719C	F	56	IV	White	Former	Afatinib	36.2	Erlotinib	1.4
17		F	50	IV	Asian	Never	Afatinib	N.D.
18		F	61	IV	White	Former	Dacomitinib	36.7
19		M	70	IIIA	White	Former	Osimertinib	N.D.
20		F	66	IIIB	White	Former	Osimertinib	2.6
21		F	65	IV	White	Former	Osimertinib	1
22		F	83	IV	White	Former	Osimertinib	8.4
23		F	74	IV	Asian	Never	Osimertinib	13.1
24		F	84	IV	White	Former	Osimertinib	1.9
25		M	79	IV	White	Former	Osimertinib	0.9

N.D.: not determined